Phase II/III, multi-centre, double-blind, parallel assignment, randomized, placebo-controlled study to evaluate the preventive effect of BGP-15 on the hospitalisation of newly diagnosed COVID-19 patients
Latest Information Update: 17 Feb 2022
Price :
$35 *
At a glance
- Drugs BGP 15 (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Mitochon Technologies
- 17 Feb 2022 Status changed to discontinued.
- 23 Jan 2022 Status changed from recruiting to completed.
- 11 Mar 2021 New trial record